drugset
drugset / Trial / NCT02759666

A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors

NCT02759666 ↗

Phase 1 Completed 30 enrolled Atridia Pty Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, non-randomized, dose-escalation phase 1 trial to evaluate the safety and tolerability of SHR3162 in participants with advanced solid tumors.

Timeline

Start
2016-06-01
Primary completion
2019-03-08
Completion
2019-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluzoparib Small molecule — Oral

Indications

neoplasm